Biogen Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Feb 14, 2024 and accepted by EDGAR at Feb 13, 2024, 17:40 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | $9.84bn | us-gaap:Revenues |
| Cost of revenue | 12 months2023-01-01 to 2023-12-31 | $2.53bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 12 months2023-01-01 to 2023-12-31 | $2.55bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $246.9m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | $135.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | $1.16bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | $7.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | $8.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 145,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | $1.55bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $277.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2023-01-01 to 2023-12-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | At period end2023-12-31 | $6.86bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $26.84bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $3.43bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $12.05bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $6.94bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2023-12-31 | $150.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-12-31 | $14.80bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875045-24-000009. Last ingested by Listed: Nov 2, 2026, 20:22 ET. Listed shows no prices and gives no investment advice.